Corline Biomedical AB (CLBIO.ST)
SEK 8.98
(-3.23%)
SEK 8.98
(-3.23%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.8 Million SEK | -177.67% |
| 2022 | 2.32 Million SEK | 133.68% |
| 2021 | -6.91 Million SEK | 5.09% |
| 2020 | -7.28 Million SEK | 23.62% |
| 2019 | -9.54 Million SEK | -40.44% |
| 2018 | -6.79 Million SEK | 13.02% |
| 2017 | -7.81 Million SEK | -48.82% |
| 2016 | -5.24 Million SEK | 10.22% |
| 2015 | -5.84 Million SEK | -132.68% |
| 2014 | -2.51 Million SEK | -0.98% |
| 2013 | -2.48 Million SEK | -172.94% |
| 2012 | -911.47 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -4.36 Million SEK | -161.93% |
| 2024 Q1 | -1.66 Million SEK | -178.0% |
| 2023 Q2 | -2.4 Million SEK | -335.98% |
| 2023 Q1 | 1.02 Million SEK | 200.88% |
| 2023 FY | -1.8 Million SEK | -177.67% |
| 2023 Q3 | 179 Thousand SEK | 107.44% |
| 2023 Q4 | -600 Thousand SEK | -435.2% |
| 2022 Q4 | 339 Thousand SEK | -82.76% |
| 2022 FY | 2.32 Million SEK | 133.68% |
| 2022 Q3 | 1.96 Million SEK | 124.69% |
| 2022 Q2 | 875 Thousand SEK | 202.7% |
| 2022 Q1 | -852 Thousand SEK | 33.85% |
| 2021 Q1 | -1.4 Million SEK | -2454.55% |
| 2021 Q4 | -1.28 Million SEK | 37.96% |
| 2021 Q2 | -2.15 Million SEK | -53.24% |
| 2021 Q3 | -2.07 Million SEK | 3.58% |
| 2021 FY | -6.91 Million SEK | 5.09% |
| 2020 Q1 | -2.5 Million SEK | -18.48% |
| 2020 Q3 | -2.15 Million SEK | 16.5% |
| 2020 Q4 | -55 Thousand SEK | 97.44% |
| 2020 FY | -7.28 Million SEK | 23.62% |
| 2020 Q2 | -2.57 Million SEK | -2.71% |
| 2019 Q2 | -2.52 Million SEK | 14.9% |
| 2019 Q1 | -2.96 Million SEK | -77.77% |
| 2019 Q3 | -1.93 Million SEK | 23.49% |
| 2019 FY | -9.54 Million SEK | -40.44% |
| 2019 Q4 | -2.11 Million SEK | -9.52% |
| 2018 FY | -6.79 Million SEK | 13.02% |
| 2018 Q4 | -1.66 Million SEK | -13.54% |
| 2018 Q1 | -1.78 Million SEK | -4.94% |
| 2018 Q3 | -1.47 Million SEK | 21.39% |
| 2018 Q2 | -1.87 Million SEK | -4.82% |
| 2017 FY | -7.81 Million SEK | -48.82% |
| 2017 Q2 | -2.03 Million SEK | 33.94% |
| 2017 Q3 | -987 Thousand SEK | 51.57% |
| 2017 Q4 | -1.7 Million SEK | -72.24% |
| 2017 Q1 | -3.08 Million SEK | -102.43% |
| 2016 Q2 | -575 Thousand SEK | 68.66% |
| 2016 FY | -5.24 Million SEK | 10.22% |
| 2016 Q1 | -1.83 Million SEK | 17.66% |
| 2016 Q4 | -1.52 Million SEK | -15.98% |
| 2016 Q3 | -1.31 Million SEK | -128.52% |
| 2015 Q4 | -2.22 Million SEK | -108.6% |
| 2015 FY | -5.84 Million SEK | -132.68% |
| 2015 Q1 | -1.11 Million SEK | -100.36% |
| 2015 Q2 | -1.43 Million SEK | -29.3% |
| 2015 Q3 | -1.06 Million SEK | 25.67% |
| 2014 Q3 | -626.74 Thousand SEK | -17.53% |
| 2014 Q4 | -554.76 Thousand SEK | 11.49% |
| 2014 FY | -2.51 Million SEK | -0.98% |
| 2014 Q2 | -533.24 Thousand SEK | 0.0% |
| 2013 FY | -2.48 Million SEK | -172.94% |
| 2012 FY | -911.47 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| 2cureX AB (publ) | -32.51 Million SEK | 94.437% |
| Abliva AB (publ) | -95.5 Million SEK | 98.106% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 98.345% |
| AcouSort AB (publ) | -17.08 Million SEK | 89.414% |
| Active Biotech AB (publ) | -45.8 Million SEK | 96.05% |
| Alzinova AB (publ) | -16.48 Million SEK | 89.023% |
| Amniotics AB (publ) | -30.87 Million SEK | 94.14% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 95.894% |
| Aptahem AB (publ) | -11.11 Million SEK | 83.722% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | 85.898% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 99.272% |
| BioInvent International AB (publ) | -330.3 Million SEK | 99.452% |
| BioArctic AB (publ) | 229.24 Million SEK | 100.789% |
| Biosergen AB | -27.03 Million SEK | 93.309% |
| Biovica International AB (publ) | -124.82 Million SEK | 98.551% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 96.816% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 99.612% |
| Camurus AB (publ) | 431.44 Million SEK | 100.419% |
| Cantargia AB (publ) | -280.02 Million SEK | 99.354% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | 91.423% |
| CombiGene AB (publ) | -35.66 Million SEK | 94.928% |
| Cyxone AB (publ) | -22.98 Million SEK | 92.131% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | 84.509% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 98.809% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 99.447% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | 88.968% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 98.021% |
| Fluicell AB (publ) | -26.55 Million SEK | 93.187% |
| Genovis AB (publ.) | 61.5 Million SEK | 102.941% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 98.404% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 99.782% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 98.53% |
| Mendus AB (publ) | -101.61 Million SEK | 98.22% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 98.983% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 95.12% |
| I-Tech AB | 20.2 Million SEK | 108.954% |
| Intervacc AB (publ) | -102.85 Million SEK | 98.241% |
| Kancera AB (publ) | -64.88 Million SEK | 97.212% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 133.587% |
| LIDDS AB (publ) | -40.2 Million SEK | 95.501% |
| Lipum AB (publ) | -37.17 Million SEK | 95.134% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | 85.084% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 114.866% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | 89.892% |
| Nanologica AB (publ) | -75.15 Million SEK | 97.593% |
| NextCell Pharma AB | -41.95 Million SEK | 95.689% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 99.274% |
| OncoZenge AB (publ) | -15.9 Million SEK | 88.624% |
| Pila Pharma AB (publ) | -9.93 Million SEK | 81.782% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | 89.052% |
| Saniona AB (publ) | -95.81 Million SEK | 98.112% |
| Simris Alg AB (publ) | -37.3 Million SEK | 95.151% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 95.716% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -313.014% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | 92.379% |
| SynAct Pharma AB | -215.81 Million SEK | 99.162% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 99.418% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 99.534% |
| Xintela AB (publ) | -54.08 Million SEK | 96.655% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 98.993% |
| Ziccum AB (publ) | -21.41 Million SEK | 91.551% |